the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Catalog | E-mail Alert | Custom Research | About The Infoshop | Contact Us | Site Map |

* View All Categories
Japanese Korean Chinese

[Report]

Stakeholder Insight: Atrial Fibrillation - Limited efficacy and poor safety lead to bleak outlook

Published: 2006/10

Contact 24 hrs/day
Table of Contents

Abstract

Overview

Introduction

Datamonitor estimates that there are over 11 million atrial fibrillation patients in the seven major markets. Despite high unmet needs and limitations of all the current treatment options, achievement of regulatory approval is becoming increasingly difficult. This means that a very limited number of novel treatments are expected to be introduced in the near future.

Scope

  • Review of the available epidemiology data to assess the patient population of atrial fibrillation and to segment the patient population by type
  • Outline of the existing therapy options and current prescribing trends
  • Assessment of the current status of the rhythm versus rate control debate and the determining factors for each type of treatment strategy
  • Evaluation of the current usage of cardiac rhythm devices and ablation techniques in order to determine their future role in AF management

Report Highlights

The rapid increase in atrial fibrillation prevalence is driven by a number of factors, namely ageing population, the obesity epidemic, better prevention of strokes, and better survival of patients with cardiac disease.

There are numerous unmet needs associated with every treatment option available. The main unmet needs of pharmacological therapy are insufficient efficacy and poor safety. Non-pharmacological therapy has severe limitations, among them the cost of the procedures and the fact that a limited number of patients are eligible for it.

Despite the desperate need for a new efficacious and safe antiarrhythmic, no new drug that would significantly impact atrial fibrillation management is going to appear in the nearest future.

Reasons to Purchase

  • Target physicians more effectively, through an understanding of treatment options and prescription choices
  • Assess the potential of each treatment option in the management of atrial fibrillation and understand the dynamics of the market
  • Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products
Table of Contents

[Report]
Stakeholder Insight: Atrial Fibrillation - Limited efficacy and poor safety lead to bleak outlook
Published: 2006/10
Published by : Datamonitor Datamonitor

Price:
US $ 15,200.00 PDF by E-mail (Single User License)
>
Product Code : DC45845
Please inform me when related publications are released
InfoWatch

Available 24 Hours a Day
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2008, the-infoshop.com by Global Information, Inc. All rights reserved.